+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

P53 overexpression in head and neck carcinoma and radiotherapy results



P53 overexpression in head and neck carcinoma and radiotherapy results



British Journal Of Cancer. 74(Suppl. 28): 34



Purpose: P53 gene mutations are the common genetic changes encountered in human cancers, and there is extensive evidence that the P53 status may determine tumor response to therapy. This study was carried out to investigate whether there is any correlation between accumulation (overexpression) of P53 protein and poor prognosis in patients with head and neck carcinomas treated with radical radiotherapy. Methods and Materials: Seventy-nine patients with head and neck carcinomas who were diagnosed and treated in 1989-90 with curative radiotherapy were studied retrospectively. Paraffin sections from archival material were studied using immunohistochemical staining (IHC) with mouse monoclonal antibodies (DO7) to human P53 protein. Univariate and multivariate analysis of loco-regional tumor control and patient survival were performed on possible prognostic factors. Results: Forty-two (53%) patients showed positive IHC staining in their tumors. Fifty-three percent of the laryngeal, 64% of the oropharyngeal, and 43% of the oral cavity carcinomas showed P53 overexpression. All tumor specimens with vascular, lymphatic, and/or sarcolemmal invasion showed P53 overexpression. The proportion of tumor-stained nuclei was higher in the poorly differentiated than in the well and moderately differentiated tumors (p lt 0.05), but there was no correlation with the patient overall or disease-free 5-year actuarial survival. There was no difference in the 5-year actuarial survival and disease-free survival between patients with P53 immunostaining in their tumors and those with no immunostaining (59% vs. 65% and 57% vs. 51%, respectively). The TNM tumor stage was the most significant prognostic factor with 5-year actuarial survival of 87% for early and 14% for late stages (p ltoreq 0.0001). There was a significant correlation between immunostaining and history of smoking (p = 0.02). Conclusion: The data demonstrate that the P53 accumulation as detected by immunohistochemical staining in a group of head and neck carcinomas was not predictive of patient's poor survival or disease-free survival. Multivariate statistical analysis showed that the TNM tumor stage was the only significant prognostic factor. There was a significant association between P53 accumulation and smoking.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 009150529

Download citation: RISBibTeXText

PMID: 8567333

DOI: 10.1016/0360-3016(95)02108-6


Related references

Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma. Cancer Research 62(22): 6414-6417, 2002

Concomittant chemo-radiotherapy versus radiotherapy in advanced squamous cell carcinoma of head and neck Results of a prospective trial. International Journal of Cancer Suppl. (13): 459, 2002

Overexpression of the nuclear factor-kappa B (p65) in association with local failure in patients with head and neck carcinoma undergong radiotherapy or chemoradiotherapy. Head and Neck 35(3): 370-375, 2013

The Leeds results for radiotherapy in HBO for carcinoma of the head and neck. Clinical Radiology 30(5): 591-592, 1979

Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. Journal of Clinical Oncology 22(1): 69-76, 2004

Prevalence and Outcomes of Head and Neck versus Non-Head and Neck Second Primary Malignancies in Head and Neck Squamous Cell Carcinoma: An Analysis of the Surveillance, Epidemiology, and End Results Database. Orl; Journal for Oto-Rhino-Laryngology and its Related Specialties 78(2): 61-69, 2016

Prospective randomized controlled trial to compare 3-dimensional conformal radiotherapy to intensity-modulated radiotherapy in head and neck squamous cell carcinoma: Long-term results. Head and Neck 38(Suppl. 1): E1481, 2016

Cervical neck dissection for complete responders in head-and-neck: a utilitarian ideal? In regard to Thariat et al "Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma." (Int J Radiat Oncol Biol Phys 2012;82:e367-e374). International Journal of Radiation Oncology, Biology, Physics 83(3): 768-768, 2012

Head and neck squamous cell carcinoma of unknown primary: neck dissection and radiotherapy or definitive radiotherapy. Head and Neck 36(11): 1589-1595, 2014

Feasibility and early results of accelerated radiotherapy for head and neck carcinoma in the elderly. Cancer 88(3): 648-652, 2000

Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial. Head and Neck 38(2): 202-207, 2016

Results of continuous, hyperfractionated, accelerated radiotherapy in squamous cell carcinoma of the head and neck. Johnson, J T, Didolkar, M S International Congress Series; Head and neck cancer: 159-163, 1993

Modified fractionated radiotherapy in head and neck squamous cell carcinoma (HNSCC) & re-irradiation in recurrent head and neck carcinomas. Cancer Treatment and Research 114: 199-212, 2003

Prognostic value of 99Tc-methoxyisobutilisonitrile , Ki-67 and p53 in head and neck carcinoma treated with chemo-radiotherapy Preliminary results. EJC Suppl.s 1(5): S50-S51, 2003

Five-years synchronized radiotherapy in treatment of carcinoma of the head and neck: clinical results, 1970--1974. Hno 24(9): 301-305, 1976